The Analyst Landscape: 4 Takes On Chemours
Portfolio Pulse from Benzinga Insights
Analysts' ratings for Chemours (NYSE:CC) over the last quarter vary from bullish to bearish. The average 12-month price target has decreased by 13.71% to $26.75. Key analysts have adjusted their ratings and price targets, reflecting changing market conditions and company performance. Chemours faces challenges with a -6.39% revenue decline but shows strong profitability with a net margin of 4.55% and an ROE of 9.49%. However, its debt-to-equity ratio of 5.86 indicates increased financial risk.
August 06, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Analysts' ratings for Chemours (NYSE:CC) vary from bullish to bearish. The average 12-month price target has decreased by 13.71% to $26.75. Chemours faces a -6.39% revenue decline but shows strong profitability with a net margin of 4.55% and an ROE of 9.49%. However, its debt-to-equity ratio of 5.86 indicates increased financial risk.
The mixed analyst ratings and the significant decrease in the average price target suggest uncertainty in the short-term performance of Chemours. The company's strong profitability metrics are offset by its revenue decline and high debt-to-equity ratio, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100